The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. As a descendent of the BA.3 omicron subvariant that emerged in 2022, it has quickly gained attention due to its rapid spread across various countries. Currently, the Cicada variant has been detected in over 20 countries, with a notable rise in cases reported in the United States, where it has been observed in 25 states.

Health experts are closely monitoring the situation as the Cicada variant carries approximately 70 to 75 mutations in its spike protein. This significant number of mutations raises questions about its transmissibility and the effectiveness of existing vaccines. However, initial evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier strains of COVID-19.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those of previous COVID-19 strains, leading health authorities to emphasize the importance of staying vigilant.

Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, particularly among vaccinated individuals. Experts highlight that most cases can be managed at home with rest and hydration.

Despite the presence of multiple mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities continue to recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the variant.

As the Cicada variant spreads, health experts have noted that symptoms remain largely consistent with previous Omicron strains, with no new or unusual signs reported so far. However, there are concerns regarding the potential impact of the variant on vaccine efficacy due to its mutations. Some experts suggest that the current COVID-19 vaccines may not be as effective against it.

Health authorities are actively monitoring the BA.3.2 variant due to its rising presence. Observers anticipate that continued vigilance and adherence to public health guidelines will be crucial in managing the spread of this variant. As the situation evolves, details remain unconfirmed, and further updates will be essential for public awareness and safety.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on berightnews.

The emergence of the Cicada COVID variant has sparked urgent health concerns as it spreads globally, including in India. This variant, classified as BA.3.2 and part of the Omicron family, was first identified in South Africa in November 2024.

With over 70 mutations compared to the original Wuhan strain, the Cicada variant carries approximately 75 mutations in total, with more than 50 of these located in the spike protein. This raises questions about its potential to evade immunity from previous infections or vaccinations.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. However, it has not been confirmed to cause more severe illness than previous variants.

As of now, the variant has been detected in 22 countries, with the first confirmed case in the United States reported in June 2025. By January 2026, three patients in the U.S. had been confirmed to have contracted the variant, all of whom recovered.

Health officials are closely monitoring the situation. Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” The CDC emphasized the importance of tracking the spread of BA.3.2 to gather valuable information regarding its potential impact on immunity.

In India, the detection of the Cicada variant raises alarms as health authorities prepare to respond to any potential outbreaks. The situation is being closely monitored, and public health measures may be adjusted accordingly.

As the world grapples with the ongoing pandemic, the emergence of new variants like Cicada underscores the need for continued vigilance. Details remain unconfirmed regarding the variant’s severity and its implications for public health.

The post Cicada COVID Variant in India Raises Concerns Amid Global Spread appeared first on berightnews.

The cicada COVID variant, known as BA.3.2, is causing alarm as it spreads across the United States. Detected in at least 25 states as of February 2026, this heavily mutated variant may evade immunity from vaccines and prior infections, raising significant public health concerns.

First identified in South Africa in November 2024, BA.3.2 has 70 to 75 mutations in its spike protein, which could reduce the effectiveness of current vaccines. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system.” This variant is classified as a ‘variant under monitoring’ by the World Health Organization since December 2025.

As of now, BA.3.2 is not causing more severe disease or hospitalizations compared to previous strains, according to Dr. Adolfo García-Sastre. However, the variant’s ability to spread primarily through respiratory particles and prolonged face-to-face interactions poses a risk for increased transmission.

In Denmark, Germany, and the Netherlands, approximately 30% of COVID-19 cases are attributed to BA.3.2. Additionally, a nationwide analysis of sewage samples indicated that 3.7% were positive for this variant, suggesting a broader presence in the community.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, and loss of smell or taste, among others. Vaccination remains crucial, as it is expected to continue providing protection against severe disease, although its effectiveness against infection may be diminished.

BA.3.2 was first detected in the U.S. in June 2025, in a traveler returning from the Netherlands. The name ‘cicada’ reflects the variant’s unusual emergence pattern, reminiscent of the insect’s lifecycle.

Despite the ongoing spread, health officials emphasize that vaccination is still vital in limiting cases. Pekosz stated, “Vaccination is still going to help limit cases.” However, uncertainties remain regarding the exact reasons for the resurgence of BA.3.2 and its long-term impact on public health. Details remain unconfirmed.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the U.S. appeared first on berightnews.